Roux-en-Y anastomosis

Glyscend Therapeutics Announces Publication of GLY-200 First-in-Human Data and Availability of Phase 2a Clinical Results

Retrieved on: 
Thursday, July 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Diabetes, Clinical Trials, Pharmacodynamics, Glycated hemoglobin, Obesity, Doctor of Philosophy, Metabolism, Diarrhea, Glucose, Weight loss, Type 2 diabetes, Constipation, Appetite, Plasma, Incidence, DSM-IV codes, Patient, AUC, Nausea, Therapy, American Diabetes Association, GI, ADA, T2D, Safety, Roux-en-Y anastomosis, Pharmaceutical industry

The data published demonstrate that GLY-200, the company’s lead clinical candidate, mimics the biomarker signature seen with metabolic surgery and appeared to be safe and generally well-tolerated.

Key Points: 
  • The data published demonstrate that GLY-200, the company’s lead clinical candidate, mimics the biomarker signature seen with metabolic surgery and appeared to be safe and generally well-tolerated.
  • Glyscend also presented additional data from its Phase 2a clinical trial of GLY-200 at the recent American Diabetes Association (ADA) 83rd Scientific Sessions, which provide clinical proof-of-concept on its ability to reduce glucose and bodyweight in patients with T2D.
  • As highlighted in the publication, safety and pharmacodynamics were assessed in a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending-dose study in healthy volunteers.
  • Data presented at ADA showed that, consistent with the Phase 1 study, no treatment- or dose-related safety signals were observed in the Phase 2a study in patients with T2D.

GI Dynamics Announces an Update to the Worldwide Registry Data for 1,022 Patients Recently Published in Diabetes Care, the Journal of the American Diabetes Association

Retrieved on: 
Tuesday, April 4, 2023
Diabetes, Medical Devices, Hospitals, Health, Clinical Trials, Blood pressure, Macrovascular disease, Type 2 diabetes, Cholesterol, Cardiovascular disease, Risk, ABCD, Patient, Collection, T2D, Safety, Roux-en-Y anastomosis, City Hospital, Pharmaceutical industry, Glycated hemoglobin, Diabetes Care, Obesity

The article recently published in Diabetes Care, “Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide,” authored by Robert Ryder, M.D.

Key Points: 
  • The article recently published in Diabetes Care, “Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide,” authored by Robert Ryder, M.D.
  • of City Hospital, Birmingham, U.K, demonstrates treatment with EndoBarrier reduced microvascular and macrovascular risk factors that could reduce the complications of type 2 diabetes (T2D).
  • Over 3,000 patients have been treated with EndoBarrier worldwide, and in 2017 a secure, online registry was established by ABCD for the collection of safety and efficacy data for EndoBarrier treated patients worldwide.
  • The ABCD Worldwide EndoBarrier Registry, led by Dr. Ryder, collected data from 34 centers in ten countries.

United Kingdom Bariatric Surgical Devices Market Report 2022: Implantable Devices v/s Assisting Devices - Competition, Forecast & Opportunities, 2017-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 27, 2023
Surgery, Health, Medical Devices, Stomach, Sleeve, Internal bleeding, Smoking, Ventricular assist device, SG, Investment, Bypass surgery, Procedure, Obesity, Research, Roux-en-Y anastomosis, FDA, Growth, Surgeon, Medical device, Dentistry

The "United Kingdom Bariatric Surgical Devices Market, By Type (Implantable Devices v/s Assisting Devices), By Procedure, By End User, By Region, Competition Forecast & Opportunities, 2017-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United Kingdom Bariatric Surgical Devices Market, By Type (Implantable Devices v/s Assisting Devices), By Procedure, By End User, By Region, Competition Forecast & Opportunities, 2017-2027" report has been added to ResearchAndMarkets.com's offering.
  • The availability of surgeons specializing in bariatric surgical techniques and the growing rate of childhood obesity is anticipated to fuel the growth of the United Kingdom bariatric surgical devices market.
  • To estimate and forecast the market size of United Kingdom bariatric surgical devices market from 2022E to 2027F and growth rate until 2027F.
  • To classify and forecast the United Kingdom bariatric surgical devices market based on type, procedure, end user, region, and company.

The Weight Loss Surgery Center of LA Founder Dr. David Davtyan Points to Recently Completed 40-Year Study on Weight Loss Surgery Confirming Benefits of Bariatric Surgery

Retrieved on: 
Monday, February 13, 2023
U.S. News & World Report, UCLA, Weight loss, Obesity, Empathy, News, Patient, LOS, Diabetes, Health, Research, Mortality, Roux-en-Y anastomosis, FDA, Medical school, School, Bariatric surgery, Cardiovascular disease, Surgeon, Elective surgery, Inland Empire, Cancer, BPDS, Longevity, Dentistry, Adjustable gastric band, Medicine

LOS ANGELES, Feb. 13, 2023 /PRNewswire-PRWeb/ -- According to the recent U.S News and World Report article, "40-Year Study Finds Weight-Loss Surgery Extending Life Spans," a brand-new study published in the January edition of the Obesity medical journal, shows that weight-loss surgery could set a person's health and longevity on a different path. In the research, patients were followed for up to 40 years after they had one of four types of weight loss surgery (bariatric surgery), sleeve gastrectomy, laparoscopic adjustable gastric banding (commonly known as Lap-Band), Roux-en-Y gastric bypass, and biliopancreatic diversion with duodenal switch (BPDS). Researchers found that these patients had significant reductions in death rates from all causes (16% lower) compared to obese patients who did not have surgery. For heart disease, it was 29% lower, cancer deaths dropped by 43%, and it was down a full 72% for diabetes. The report concluded that having surgery is beneficial overall in extending life, and patients should probably have it sooner rather than later to prevent other diseases. At the Weight Loss Surgery Center of Los Angeles, a prominent weight loss center located in Beverly Hills, Dr. David Davytan performs the surgical procedures listed in the study and more to help his patients win their battle against obesity. Dr. Davtyan and his team treat every patient individually and construct personalized treatment plans that fit their unique needs and goals. The center offers a wide spectrum of cutting-edge medical endoscopic, surgical, and minimally invasive weight loss procedures combined with exceptional compassion, empathy, and expertise to provide excellent outcomes for patients.

Key Points: 
  • Leading specialist, Dr. David G. Davtyan, is board certified in surgery and is one of the top weight loss surgeons in the Los Angeles area.
  • Dr. David G. Davtyan is a highly-respected weight loss surgeon with over 28 years of experience and has treated thousands of patients with exceptional results.
  • Dr. Davtyan and his team offer top-quality weight loss surgery (bariatric surgery) and weight loss treatment in Los Angeles, Orange County, and the Inland Empire.
  • Dr. David Davytan, Weight Loss Surgery Center of Los Angeles, 877-923-7546, [email protected]

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

Retrieved on: 
Thursday, December 15, 2022
Roche, Synthetic biology, Associate, Intellectual property, TID, HCU, Genetic engineering, Clinical trial, Inflammatory bowel disease, Kidney, PKU, Absorption, Urine, FDA, Uric acid, AES, Webcast, Safety, Roux-en-Y anastomosis, Diet, Homocystinuria, Pain, Gout, Phenylketonuria, Malabsorption, MD, Risk, Șaeș, University of Alabama at Birmingham School of Medicine, Associate professor, ID, History, IBD, University, Metabolism, Patient, Therapy, Probiotic, Pharmaceutical industry, Urology, AbbVie

CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB8802 has demonstrated proof of concept through clinically significant lowering of urinary oxalate in a Phase 1b study in patients with a history of gastric bypass surgery.

Key Points: 

    AltrixBio announces issuance of US Patent for water-activated mucoadhesive composition and formulations for LuCI™ (luminal coating of the intestine).

    Retrieved on: 
    Wednesday, September 14, 2022
    Weight loss, Roux-en-Y anastomosis, Hospital, Ramakanta Panda, GI, Obesity, Diabetes, Patient, Type 2, Luci, CEO, Type 2 diabetes, Technology, Patent, Leadership, Bariatric surgery, Harvard Medical School, Research, Roy Taylor (scientist), Brigham and Women's Hospital, Pharmaceutical industry, T2D

    This is a significant milestone with respect to our intellectual property portfolio, demonstrating our ongoing commitment to innovation and leadership in this field, said Nancy Briefs, the CEO of AltrixBio.

    Key Points: 
    • This is a significant milestone with respect to our intellectual property portfolio, demonstrating our ongoing commitment to innovation and leadership in this field, said Nancy Briefs, the CEO of AltrixBio.
    • As an orally administered agent, LuCI has demonstrated in preclinical testing to be a safe, non-invasive, and effective agent that replicates the effects of Roux-en-Y gastric bypass surgery.
    • Approximately 80% of patients who have gastric bypass surgery have significant weight loss and, importantly, early and weight-independent remission of T2D.
    • They were fascinated by the rapid resolution of Type 2 Diabetes (T2D) observed in patients undergoing gastric bypass.

    Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

    Retrieved on: 
    Tuesday, April 26, 2022
    Roux-en-Y anastomosis, Engineering, Inflammatory bowel disease, Lists of diseases, Genetic engineering, Clinical trial, Synthetic biology, Chronic kidney disease, Homocysteine, US Foods, PKU, AbbVie, Homocystinuria, Food, Private Securities Litigation Reform Act, Neurotoxicity, GLOBE, Doctor of Philosophy, Risk, GI, Patient, SEED, ESRD, HCU, Frank Lenti, Probiotic, Metabolism, SEC, Roche, Phenylketonuria, Safety, Kidney, Intellectual disability, Evolution, FDA, Gastrointestinal tract, Thrombosis, Therapy, Synthetic, Pharmaceutical industry, Publication

    The poster presentations highlight preclinical and clinical data across five different Synlogic programs.

    Key Points: 
    • The poster presentations highlight preclinical and clinical data across five different Synlogic programs.
    • The presentations will be available in their respective sections of the Presentations and Publications page on the Synlogic website on the day of the presentations.
    • Data from a proof-of-concept study assessing the lowering of urinary oxalate in patients who have undergone Roux-en-Y gastric bypass surgery is expected in 2022.
    • These forward-looking statements should not be relied upon as representingSynlogic'sview as of any date subsequent to the date hereof.

    RSIP Vision Presents New Technology for Intra-op Virtual Measurements in Laparoscopic and Robotic-Assisted Surgeries

    Retrieved on: 
    Tuesday, January 25, 2022
    Software, Other Health, Optical, Data Management, Oncology, Technology, Medical Devices, Hospitals, Surgery, Biotechnology, Nursing, Medical Supplies, Health, Medical device, Trauma, Malabsorption, Artificial intelligence, RSIP, Gastrectomy, Industry, Reflux, CA, Elective surgery, Software, Rambam Health Care Campus, Roux-en-Y anastomosis, Calibration, Multimedia, Ischemia, Hand, Bariatric surgery, Pylorus, Tissue, Technology, Bowel obstruction, Inflammation, Whipple, CEO, Medical imaging

    Presently, Laparoscopic and Robotic Assisted Surgeries use a real-time video feed for guidance, which is not fully utilized, said Ron Soferman, CEO at RSIP Vision.

    Key Points: 
    • Presently, Laparoscopic and Robotic Assisted Surgeries use a real-time video feed for guidance, which is not fully utilized, said Ron Soferman, CEO at RSIP Vision.
    • Leveraging RSIP Visions deep learning-based landmark detection technology, the tool tip is automatically tracked, enabling virtual measurements without introduction of a physical ruler into the scene.
    • RSIP Vision is driving innovation in Visual Intelligence for Medical Devices, through advanced AI and computer vision applications.
    • RSIP Vision is headquartered in Jerusalem, and has a U.S. office in San Jose, CA.

    Synlogic Announces Progress Toward 2022 Clinical Milestones and Participation at Upcoming Investor Conferences

    Retrieved on: 
    Thursday, January 6, 2022
    Clinical trial, Safety, BIO, PKU, Food, Chronic kidney disease, US Foods, Therapy, Gastrointestinal tract, Patient, Neurotoxicity, Inflammatory bowel disease, Intellectual disability, Lists of diseases, Frank Lenti, Conference, Probiotic, Risk, Private Securities Litigation Reform Act, SEC, HCU, GI, FDA, Genetic engineering, Homocysteine, Roux-en-Y anastomosis, ESRD, Kidney, Thrombosis, Homocystinuria, Industry, Metabolism, Synthetic biology, Roche, Phenylketonuria, Public relations, Video game, Pharmaceutical industry, AbbVie

    CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today provided an update on progress towards multiple 2022 clinical milestones.

    Key Points: 
    • Synlogic will present a corporate update at the H.C. Wainwright BIOCONNECT Virtual Conference taking place from January 10-13, 2022.
    • The recorded presentation will be available beginning Monday, January 10, 2022, at 7:00 a.m. Eastern Time.
    • Synlogic will attend and present at the 2022 BIO CEO & Investor Conference taking place virtually and in-person from February 14-17, 2022, in New York City.
    • Synlogic will attend and present at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022.

    Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021

    Retrieved on: 
    Friday, October 15, 2021
    History, Private Securities Litigation Reform Act, Nasdaq, Metabolic disorder, Lists of diseases, UOX, Risk, Hyperoxaluria, Cancer, Urine, PKU, Metabolism, Diet, Engineering, Synthetic biology, Absorption, Therapy, Nephrocalcinosis, Disease, Medicine, Roux-en-Y anastomosis, Clinical trial, American Society of Nephrology, Biology, Intellectual property, Society, ASN, Poster, Collection, Odds ratio, Chronic kidney disease, Kidney, Inflammatory bowel disease, Short bowel syndrome, Pharmaceutical industry

    CAMBRIDGE, Mass., Oct. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster presentations at the upcoming American Society for Nephrology (ASN) Kidney Week 2021, to be held virtually November 4 7th, 2021.

    Key Points: 
    • CAMBRIDGE, Mass., Oct. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster presentations at the upcoming American Society for Nephrology (ASN) Kidney Week 2021, to be held virtually November 4 7th, 2021.
    • At this dose, the percent reduction from baseline UOx levels was -28.6% (90% CI: -42.4 to -11.6) compared to placebo in diet-induced hyperoxaluria.
    • Enteric Hyperoxaluria results in dangerously high levels of urinary oxalate, which causes progressive kidney damage, kidney stone formation, and nephrocalcinosis.
    • However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so.